Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.03 (-16.22%)
Close on Nov 13, 2026Market cap $3.34MP/E –Yield –
Mangoceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Mangoceuticals's gross margin for the twelve months ending Jun 30, 2026 was 54.4%. For fiscal 2025 it was 54.9%, against 61.7% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 54.9% | −6.8 |
| FY2024 | Dec 31, 2024 | 61.7% | +2.7 |
| FY2023 | Dec 31, 2023 | 59.0% | +4.7 |
| FY2022 | Dec 31, 2022 | 54.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 64.3% | +10.8 |
| Q1 FY2026 | Mar 31, 2026 | 42.7% | −14.0 |
| Q4 FY2025 | Dec 31, 2025 | 50.3% | −25.8 |
| Q3 FY2025 | Sep 30, 2025 | 60.4% | −1.6 |
| Q2 FY2025 | Jun 30, 2025 | 53.5% | +10.7 |
| Q1 FY2025 | Mar 31, 2025 | 56.8% | −12.1 |
| Q4 FY2024 | Dec 31, 2024 | 76.1% | +17.8 |
| Q3 FY2024 | Sep 30, 2024 | 62.0% | +3.0 |
| Q2 FY2024 | Jun 30, 2024 | 42.8% | −18.9 |
| Q1 FY2024 | Mar 31, 2024 | 68.8% | +12.1 |
| Q4 FY2023 | Dec 31, 2023 | 58.3% | – |
| Q3 FY2023 | Sep 30, 2023 | 59.0% | – |
| Q2 FY2023 | Jun 30, 2023 | 61.7% | – |
| Q1 FY2023 | Mar 31, 2023 | 56.8% | – |
See a number that looks wrong?